phrykt

Climb Bio, Inc. (CLYM): who owns it and who trades it

As of Nov 16, 2026, CLYM insiders reported 6 open-market sales worth $2.7M and 3 purchases worth $780K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Stephen Basil Thomas (Director), with $2.2M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Climb Bio

From the latest filings

Overall: about as much buying as selling. Insiders and famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CLYM

109 funds and institutions reported CLYM shares worth $736M at the end of Q2 2026, about 99% of the company. The largest holder is Ra Capital Management, L.P. with 19.7%.

Funds and institutions (13F) 99%Everyone else 1%

10 largest owners, by share of the company

Ra Capital Management, L.P.19.7%
FMR LLC (Fidelity)11.9%
UBS Group AG5.9%
Braidwell LP4.9%
Adage Capital Partners Gp, L.l.c.4.4%
BlackRock, Inc.4.1%
T. Rowe Price Associates3.7%
Cormorant Asset Management, LP3.7%
Frontier Capital Management Co LLC3.4%
Vanguard Capital Management LLC3.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.11.30M19.74%$147MNo change
FMR LLC (Fidelity)6.79M11.86%$88.5M+106049%
UBS Group AG3.40M5.95%$44.4M+3862%
Braidwell LP2.80M4.89%$36.5M+83%
Adage Capital Partners Gp, L.l.c.2.51M4.38%$32.7MNew
BlackRock, Inc.2.35M4.11%$30.7M+486%
T. Rowe Price Associates2.13M3.72%$27.7M+11%
Cormorant Asset Management, LP2.11M3.68%$27.5MNew
Frontier Capital Management Co LLC1.94M3.39%$25.3MNew
Vanguard Capital Management LLC1.70M2.97%$22.2M+44%
Woodline Partners LP1.58M2.76%$20.6MNew
Citadel Advisors LLC1.30M2.27%$16.9M+276%
Redmile Group, LLC1.23M2.14%$16MNew
Great Point Partners LLC1.00M1.75%$13M-25%
Affinity Asset Advisors, LLC972,0001.70%$12.7M+39%
Millennium Management LLC908,1981.59%$11.8M-29%
ADAR1 Capital Management, LLC822,6491.44%$10.7M+38%
Driehaus Capital Management LLC790,0001.38%$10.3M+31%
Geode Capital Management, LLC782,1991.37%$10.2M+150%
Stempoint Capital LP742,7451.30%$9.7MNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CLYM insiders reported $780K of open-market purchases and $2.7M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$780K
3 trades, 2 people
Sales, 12 months
$2.7M
6 trades, 2 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Sep 15, 2026
Filed Sep 17, 2026

Purchases and sales by month

$1.4M$1.4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 15, 2026Stephen Basil ThomasDirectorSale100,000$13.67$1.4MForm 4
Jun 29, 2026Aoife BrennanCEOSale30,902$13.17$407KForm 4
Feb 26, 2026Stephen Basil ThomasDirectorSale16,313$7.01$114KForm 4
Feb 25, 2026Stephen Basil ThomasDirectorSale33,687$7.00$236KForm 4
Feb 13, 2026Stephen Basil ThomasDirectorSale10,000$5.81$58.1KForm 4
Feb 12, 2026Stephen Basil ThomasDirectorSale90,000$5.23$471KForm 4
Jan 5, 2026RA Capital Healthcare Fund LP +6DirectorPurchase7,111$3.50$24.9KForm 4
Dec 12, 2025Peter Kolchinsky +6DirectorPurchase101,462$2.86$290KForm 4
Dec 11, 2025Peter Kolchinsky +6DirectorPurchase213,099$2.18$465KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Stephen Basil ThomasDirector–$2.2MSep 15, 2026
Peter KolchinskyDirector, 10% owner$755K–Dec 12, 2025
Aoife BrennanPresident and CEO, Director–$407KJun 29, 2026
RA Capital Healthcare Fund LPDirector, 10% owner$24.9K–Jan 5, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CLYM short interest

High short interest. 18.1% of CLYM shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 408%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 10.61M CLYM shares were sold short, 18.1% of the shares outstanding, up 8.5% from the report before. At the average daily volume of 1.37M shares, buying them all back would take about 7.8 trading days (days to cover).

Shares short, % of all shares

18.1%May 15Oct 3020.3%

Days to cover

7.8May 15Oct 3011.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202610.61M18.07%+8%1.37M7.8
Oct 15, 20269.79M17.04%+1%946,17810.3
Sep 30, 20269.72M16.92%+14%1.72M5.6
Sep 15, 20268.51M14.81%+17%1.88M4.5
Aug 31, 20267.30M12.71%-3%1.23M5.9
Aug 14, 20267.56M13.16%+7%1.20M6.3
Jul 31, 20267.04M12.25%+2%1.04M6.8
Jul 15, 20266.87M12.00%+35%1.36M5.0
Jun 30, 20265.10M8.90%+70%1.73M3.0
Jun 15, 20263.00M5.24%+57%1.53M2.0
May 29, 20261.91M3.33%-9%676,3272.8
May 15, 20262.09M3.65%+18%972,9702.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Climb Bio company events

Climb Bio filed 19 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 26, 2026AnnouncementThe Company announced initial PrisMN Phase 2 data for budoprutug, its anti-CD19 monoclonal antibody, in pMN and minimal change disease. Filing
  3. Oct 23, 2026AnnouncementThe Company announced additional data from the Phase 1 clinical development program of CLYM116 in healthy volunteers. Filing
  4. Sep 3, 2026AnnouncementShared information with investors. Filing
  5. Aug 14, 2026AnnouncementBeijing Mabworks Biotech Co., Ltd. announced the dosing of the first patient with immunoglobulin A nephropathy in a Phase 2 clinical trial in China, which is being conducted in collaboration with Climb Bio, Inc. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the… Filing
  6. Aug 6, 2026ResultsReleased financial results. Filing
  7. Jul 1, 2026LeadershipAndrew Levin notified the board of directors of Climb Bio, Inc. of his resignation as a member of the Board, effective immediately. Filing
  8. Jun 12, 2026AgreementClimb Bio, Inc., a Delaware corporation, entered into an Open Market Sale Agreement℠ with Jefferies LLC, as agent, pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share, from time to time through Jefferies. Filing
  9. Jun 11, 2026AnnouncementClimb Bio, Inc. announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia: • The Phase 1b portion of the Phase 1b/2a study (NCT07043946) is evaluating three ascending… Filing
  10. Jun 8, 2026LeadershipAt the 2026 Annual Meeting of Stockholders of Climb Bio, Inc. held on June 5, 2026, the Company’s stockholders approved an amendment to the Company’s 2021 Equity Incentive Plan to amend the provision providing for an automatic share pool increase to include prefunded warrants in the calculation of… Filing
  11. Jun 5, 2026AnnouncementClimb Bio, Inc. announced translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, its anti-APRIL monoclonal antibody: • A translational pharmacokinetic/pharmacodynamic model derived from pooled non-human primate data projected healthy human exposure and dose-dependent IgA… Filing
  12. May 7, 2026ResultsReleased financial results. Filing
  13. May 5, 2026AnnouncementShared information with investors. Filing
  14. Apr 28, 2026AgreementClimb Bio, Inc., a Delaware corporation, entered into a securities purchase agreement with certain institutional accredited investors, including an affiliate of RA Capital Management, pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of… Filing
  15. Apr 3, 2026LeadershipClimb Bio, Inc. and Cindy Driscoll, its Senior Vice President, Finance and principal accounting officer, mutually agreed that Ms. Driscoll would separate from the Company, effective April 30, 2026. Filing
  16. Mar 5, 2026ResultsReleased financial results. Filing
  17. Jan 8, 2026AnnouncementThe Company issued a press release announcing its pipeline progress and anticipated milestones for 2026, including the following pipeline updates: • In November 2025, the Company dosed the first patient in its PrisMN Phase 2 clinical trial of budoprutug in primary membranous nephropathy. • In… Filing
  18. Dec 31, 2025AnnouncementClimb Bio, Inc. filed a complaint in Delaware Superior Court against Alumis Inc. and its wholly owned subsidiary, Acelyrin, Inc., relating to a dispute concerning an Asset Purchase Agreement, dated as of January 11, 2024, between Acelyrin and Tenet Medicines, Inc., a wholly owned subsidiary of the… Filing
  19. Dec 11, 2025AgreementClimb Bio, Inc. entered into an exchange agreement with RA Capital Management, L.P. and an entity affiliated with RA Capital, pursuant to which the Exchanging Stockholder agreed to exchange an aggregate of 20,440,000 shares of the Company’s common stock, par value $0.0001 per share, beneficially… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Climb Bio financials

Famous investors that hold CLYM

4 of the 50 well-known investors we track reported holding CLYM in their latest 13F filing. The largest position is Ken Griffin's, worth $5.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026452,732$5.2M0.0%-65%
Israel Englander · Millennium ManagementQ3 2026104,976$1.2M0.0%-88%
Jim Simons · Renaissance TechnologiesQ3 202670,200$805K0.0%-64%
Ken Fisher · Fisher Asset ManagementQ3 202643,996$505K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named CLYM in the last 120 days.

FiledHolderFormStake
Nov 9, 2026RA Capital Management, L.P.13D/A33.0%
Nov 9, 2026RA Capital Management, L.P.13D/A33.0%
Nov 5, 2026FMR LLC13G/A15.0%
Nov 5, 2026FMR LLC13G/A15.0%
Oct 28, 2026Deerfield Mgmt, L.P.13G5.2%
Oct 28, 2026Deerfield Mgmt, L.P.13G5.2%
Oct 27, 2026BlackRock, Inc.13G5.0%
Oct 27, 2026BlackRock, Inc.13G5.0%

Questions about Climb Bio, Inc. (CLYM) stock

Who owns the most CLYM stock?

The largest reported owner of Climb Bio, Inc. (CLYM) is Ra Capital Management, L.P., with 19.7% of the company. In total, 109 funds and institutions reported holding CLYM at the end of Q2 2026, together about 99% of the shares. See the largest owners.

Are CLYM insiders buying or selling?

In the last 12 months, CLYM insiders reported 3 open-market purchases worth $780K and 6 sales worth $2.7M. The latest trade was on Sep 15, 2026. See every trade.

What is the short interest in CLYM?

As of Oct 30, 2026, 10.61M CLYM shares were sold short, 18.1% of the shares outstanding, up 8.5% from the report before. At the average daily volume of 1.37M shares, buying them all back would take about 7.8 trading days (days to cover). See the history.

Which famous investors hold CLYM?

4 of the 50 well-known investors we track reported CLYM in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $5.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.